Hybio Pharmaceutical Co., Ltd.
300199
Kedudukan dalam Saham
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Harga Saham
$3.69
Modal Pasaran
$3.11B
Perubahan (1 hari)
-7.75%
Perubahan (1 tahun)
21.56%
Negara
CN
Perdagangan Hybio Pharmaceutical Co., Ltd. (300199)
Kategori
Healthcare
Hasil untuk Hybio Pharmaceutical Co., Ltd. (300199)
Hasil pada Jun 2026 TTM: $165.50M
Menurut laporan kewangan terkini daripada Hybio Pharmaceutical Co., Ltd., hasil semasa syarikat (TTM) ialah $165.50M. Pada tahun 2024, syarikat memperoleh hasil sebanyak $80.86M peningkatan berbanding hasil pada tahun 2023 iaitu $60.94M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Hybio Pharmaceutical Co., Ltd. dari 2007 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $165.50M | 19.82% |
| 2025 | $138.12M | 70.82% |
| 2024 | $80.86M | 32.68% |
| 2023 | $60.94M | -40.32% |
| 2022 | $102.11M | -11.82% |
| 2021 | $115.79M | 4.81% |
| 2020 | $110.48M | 25.25% |
| 2019 | $88.20M | -52.02% |
| 2018 | $183.82M | -4.03% |
| 2017 | $191.55M | 55.53% |
| 2016 | $123.15M | 4.10% |
| 2015 | $118.31M | 74.71% |
| 2014 | $67.72M | 36.28% |
| 2013 | $49.69M | 38.99% |
| 2012 | $35.75M | 38.27% |
| 2011 | $25.86M | 39.97% |
| 2010 | $18.47M | 36.03% |
| 2009 | $13.58M | 19.78% |
| 2008 | $11.34M | 47.29% |
| 2007 | $7.70M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $23.54B | 14,121.00% |
DE
|
|
| $23.73B | 14,241.61% |
DE
|
|
| $29.24B | 17,567.76% |
JP
|
|
| $5.85B | 3,434.05% |
CH
|
|
| $6.61B | 3,895.03% |
IN
|
